Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncogene
Auteurs principaux: Yang, H, Kircher, D A, Kim, K H, Grossmann, A H, VanBrocklin, M W, Holmen, S L, Robinson, J P
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2017
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501768/
https://ncbi.nlm.nih.gov/pubmed/28263969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.526
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires